Bronchiolitis Obliterans Syndrome Global Market Report 2025

The bronchiolitis obliterans syndrome market size has grown strongly in recent years. It will grow from $1.46 billion in 2024 to $1.59 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. Growth during the historical period can be attributed to the rising incidence of post-transplant complications, increased awareness among healthcare professionals, expanded use of immunosuppressive therapies, a heightened research focus on rare pulmonary conditions, and the growing adoption of advanced diagnostic imaging and lung function testing.

The bronchiolitis obliterans syndrome market size is expected to see strong growth in the next few years. It will grow to $2.23 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. Growth in the forecast period can be attributed to the global rise in lung transplant procedures, an expanding pipeline of targeted therapies for BOS, increased government and private funding for orphan diseases, growing collaborations and licensing agreements, and a rising demand for personalized medicine and biomarker-based approaches. Key trends expected during this period include progress in inhaled drug delivery technologies, the integration of artificial intelligence in pulmonary diagnostics, technology-enabled advancements in precision medicine, developments in bioinformatics and clinical trial analytics, and innovations in immunomodulatory therapies.

The increasing number of lung transplantations is anticipated to drive the growth of the bronchiolitis obliterans syndrome (BOS) market in the coming years. Lung transplantation is a surgical procedure in which a diseased or non-functioning lung is replaced with a healthy lung from a donor to enhance respiratory function. The rise in lung transplants is attributed to advancements in surgical techniques that have improved success rates and reduced complications, making the procedure safer and more widely available to patients. For individuals with advanced BOS, lung transplantation offers an effective treatment option by restoring lung function and easing breathing difficulties. For example, in January 2025, the Organ Procurement and Transplantation Network, a U.S.-based nonprofit scientific and educational organization, reported that lung transplants experienced the highest proportional growth, rising from 3,026 in 2023 to 3,340 in 2024 - an increase of 10.4%. Thus, the rising number of lung transplant procedures is contributing significantly to the expansion of the bronchiolitis obliterans syndrome market.

The rising number of clinical trials is expected to drive the growth of the bronchiolitis obliterans syndrome (BOS) market in the coming years. Clinical trials are research studies conducted in humans to assess the safety, efficacy, and effectiveness of medical interventions, including drugs, devices, procedures, and behavioral therapies. This increase in clinical trials is fueled by the growing demand for personalized medicine, which necessitates more studies to validate targeted and gene-based treatments. In the context of BOS, clinical trials play a crucial role in evaluating new therapies that aim to reduce inflammation and preserve lung function, while also advancing the understanding of disease progression and treatment safety. For instance, in November 2023, the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade group, reported a 4.3% increase in the number of industry-sponsored clinical trials launched in the UK, rising from 394 in 2021 to 411 in 2022. Therefore, the growth in clinical trials is contributing significantly to the expansion of the bronchiolitis obliterans syndrome market.

Leading companies in the bronchiolitis obliterans syndrome (BOS) market are concentrating on the development of advanced treatments such as at-home nebulized therapy to improve medication adherence and slow disease progression through targeted, continuous care. At-home nebulized therapy uses a nebulizer to convert liquid medication into a mist that can be inhaled directly into the lungs, offering a convenient and self-administered option for managing respiratory conditions from home. For example, in March 2023, Renovion, Inc., a U.S.-based clinical-stage pharmaceutical company, introduced ARINA-1, which received Fast Track Designation from the U.S. Food and Drug Administration (FDA). ARINA-1 is designed to prevent the progression of BOS in patients who have undergone bilateral lung transplants. This regulatory recognition highlights the therapy’s potential to meet a critical unmet need in transplant medicine. The Fast Track status allows for more frequent interactions with the FDA and prioritizes ARINA-1 for accelerated development and review, reinforcing Renovion’s commitment to advancing respiratory care through innovative, patient-centered treatments.

Major players in the bronchiolitis obliterans syndrome market are Pfizer Inc., Boehringer Ingelheim, University of California Health, Texas Children’s Hospital, Incyte Corporation, Apollo Hospitals, Mallinckrodt Pharmaceuticals plc, Zambon Company S.p.A., Fortis Healthcare, St. Louis Children's Hospital, Mayo Foundation for Medical Education and Research, Medicover Hospitals, Renovion Inc., Mereo BioPharma Group PLC, OrphAI Therapeutics, Koutif Therapeutics, ArkBio, Altavant Sciences, Breath Therapeutics, University of Alberta Hospital.

North America was the largest region in the bronchiolitis obliterans syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the bronchiolitis obliterans syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bronchiolitis obliterans syndrome (BOS) is a chronic, progressive lung condition characterized by inflammation and scarring that lead to the narrowing of the small airways. It commonly occurs as a complication following lung or stem cell transplantation, signaling chronic graft rejection. Early diagnosis of BOS is vital to initiate timely treatment, slow disease progression, and preserve lung function.

The primary treatment options for bronchiolitis obliterans syndrome include medication, oxygen therapy, and lung transplantation. Medications help manage BOS by reducing inflammation, slowing disease advancement, and enhancing lung performance. Diagnosis involves various methods such as pulmonary function tests, imaging studies, lung biopsies, and others, tailored to different forms of the disease, including acute bronchiolitis and chronic bronchiolitis obliterans syndrome. The treatments are utilized across multiple end users, including hospitals, specialty clinics, diagnostic centers, and other healthcare facilities.

The bronchiolitis obliterans syndrome market research report is one of a series of new reports that provides bronchiolitis obliterans syndrome market statistics, including the bronchiolitis obliterans syndrome industry global market size, regional shares, competitors with the bronchiolitis obliterans syndrome market share, detailed bronchiolitis obliterans syndrome market segments, market trends, opportunities, and any further data you may need to thrive in the bronchiolitis obliterans syndrome industry. This bronchiolitis obliterans syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bronchiolitis obliterans syndrome market consists of revenues earned by entities providing services such as psychological counseling, patient monitoring and follow-up care, nutritional support, and pulmonary rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The bronchiolitis obliterans syndrome market also includes sales of high-resolution CT (HRCT) scanner, oxygen concentrators, flexible bronchoscope, and invasive ventilators. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.